Tag Archives: Incyte

Week’s opening stock roundup: gainers include Novocure, Steadymed; but Corvus, NewLink rocked

Here to start your trading week are the major movers from last week and where they stand this morning: Novocure (Nasdaq: NVCR) led advancing issues, soaring $3.25, or 40% over the… Read more »

Gilead starts 2017 by snatching Novartis cancer specialist; a harbinger of early (and ferocious) M&A?

Gilead Sciences Inc. (Foster City CA) has poached a top cancer specialist from Swiss drugmaker Novartis AG (Basel) as the US healthcare group sharpens its focus on oncology. Alessandro Riva… Read more »